Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
24 juin 2024 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
12 juin 2024 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
27 mai 2024 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic Lugano...
Vaso Occlusive Crisis Market revenue to surpass USD 20 Billion by 2036, says Research Nester
06 déc. 2023 06h30 HE
|
Research Nester
New York, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global vaso occlusive crisis market size is projected to expand at 8% CAGR between 2024 and 2036. The market is expected to garner a revenue of USD 20...
Acute Kidney Injury Treatment Market to Reach US$ 3 Bn by 2031, TMR Study
01 déc. 2022 09h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The acute kidney injury treatment market stood at US$ 1.5 Bn in 2021. TMR projects that the...
ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch
06 févr. 2019 08h29 HE
|
ChemioCare
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company based on proprietary transdermal delivery, today announced the minipig safety and...
ChemioCare Initiates Development Program in Pediatric CINV
04 janv. 2019 17h52 HE
|
ChemioCare
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult...
Filament BioSolutions Announces Collaboration with Ajinomoto for the Development of FB-2710 for Radiation-Induced Oral Mucositis
10 juil. 2018 07h30 HE
|
Filament BioSolutions, Inc.
NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- Filament BioSolutions, a development-stage company focused on delivering innovative therapeutics for nutritional deficiencies, announced today continued...